Last reviewed · How we verify
STA 5326 mesylate — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
STA 5326 mesylate (STA 5326 mesylate) — Synta Pharmaceuticals Corp..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| STA 5326 mesylate TARGET | STA 5326 mesylate | Synta Pharmaceuticals Corp. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- STA 5326 mesylate CI watch — RSS
- STA 5326 mesylate CI watch — Atom
- STA 5326 mesylate CI watch — JSON
- STA 5326 mesylate alone — RSS
Cite this brief
Drug Landscape (2026). STA 5326 mesylate — Competitive Intelligence Brief. https://druglandscape.com/ci/sta-5326-mesylate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing